abstract |
Peptidomimetic analogs suitable for use in cancer therapy, or as antagonists of opioid drugs, and suitable application of the compounds are disclosed. The described compounds display cytostatic and cytotoxic effects toward intestinal cancer cells, and pancreatic cancer cells, display affinity to μ and δ receptors, and act as antagonists of opioid drugs. Particularly, they are intended for administration to gastrointestinal system, in the form of tablets, infusions, injections, or implants, in therapy and supporting therapy of intestinal or pancreatic cancer, and in elimination of respiratory depression triggered by opioids, and to assure appropriate intestine peristalsis during an opioid therapy. |